Mainz Biomed N.V. (NASDAQ:MYNZ), a Germany-based molecular genetics diagnostics company focused on early cancer detection, on Tuesday announced the commercial launch of its flagship colorectal cancer screening test, ColoAlert, in Switzerland.

The launch follows a strategic partnership with Swiss diagnostic laboratory labor team w ag, providing a strong distribution network for ColoAlert across the country. Following this, Swissmedic, the national therapeutic product regulator, granted official registration and marketing approval, clearing the way for market entry.

Mainz Biomed has subsequently completed a full technology transfer to labor team's facility in Goldach, enabling local processing and analysis of ColoAlert samples. This move enhances efficiency while ensuring patients receive diagnostics within Switzerland's healthcare system.

Alongside the commercial rollout, Mainz Biomed continues recruitment for its 2,000-patient eAArly DETECT 2 study, targeting completion of enrolment by the end of 2025.